Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) FCF Margin: 2022-2025

Historic FCF Margin for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to -28.57%.

  • Phathom Pharmaceuticals' FCF Margin rose 36048.00% to -28.57% in Q3 2025 from the same period last year, while for Sep 2025 it was -153.12%, marking a year-over-year increase of 78984.00%. This contributed to the annual value of -483.07% for FY2024, which is 1992954.00% up from last year.
  • As of Q3 2025, Phathom Pharmaceuticals' FCF Margin stood at -28.57%, which was up 82.03% from -158.98% recorded in Q2 2025.
  • Phathom Pharmaceuticals' 5-year FCF Margin high stood at 1,626.57% for Q1 2022, and its period low was -6,491.50% during Q4 2023.
  • Its 3-year average for FCF Margin is -1,015.40%, with a median of -213.93% in 2024.
  • In the last 5 years, Phathom Pharmaceuticals' FCF Margin slumped by 692,321bps in 2023 and then skyrocketed by 627,756bps in 2024.
  • Over the past 4 years, Phathom Pharmaceuticals' FCF Margin (Quarterly) stood at 431.71% in 2022, then slumped by 692,321bps to -6,491.50% in 2023, then spiked by 627,756bps to -213.93% in 2024, then spiked by 36,048bps to -28.57% in 2025.
  • Its FCF Margin stands at -28.57% for Q3 2025, versus -158.98% for Q2 2025 and -297.96% for Q1 2025.